{"ticker": {"uuid": "36013515-43ff-4942-b78f-aa0d34002340", "symbol": "NVS", "name": "Novartis AG ADR", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Novartis AG (NVS): 7 Best Longevity and Anti-Aging Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPckZUd2pEUzRHRV9vSDhhWWxEUDNHM3VMOUw5aHhoN0Z0S1FsY2t6ZjhQMEpNVlF3RVdIWjU2Rlh6X2JUd0t3U0tuV2xmUHhXUG9SZTlzTV9KcmJDaXMyODA4Skk4Z254QkhHdE5mNGl5MWczWlV0V3F3R0ZjZnZuS1NYb0JiTHRxdWcw?oc=5", "source_name": "Market source", "published_at": "2026-06-22T13:10:10+00:00", "published_display": "22 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NOVARTIS AG-SPONSORED ADR (NVS) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE9OTk9GT29Lc2lhZy1mYk9fclh0VDlfbmp1SWJOT0tjaV9Ld3VSMWQyT1Byek9sM2NYMUZTRk9yeUdiVk9raXE0czZTUXRiY256RjVWdWZTQ2dXdXMyMU83Sll6SQ?oc=5", "source_name": "ChartMill", "published_at": "2026-06-19T00:19:39+00:00", "published_display": "19 Jun 2026 00:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5oRllyQi14b3ZkUWN4TVRPSUNpUXZxbkFaSE1PTDZGWldOMDJpTlZMaUM4V3dTQ2FtaGZ1cmk5dnNOdWJ4Q2JYUGkxVm1VVFR0M2FBcDFXSDExQQ?oc=5", "source_name": "ChartMill", "published_at": "2026-06-19T00:19:39+00:00", "published_display": "19 Jun 2026 00:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA ratio of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs \u2013 BCBA:NVS.CI", "summary": "This article provides access to the enterprise value to EBITDA ratio for Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs, traded on the Buenos Aires Stock Exchange under the ticker NVS.CI. It appears to be a financial data page from TradingView, offering financial metrics for th", "url": "https://www.tradingview.com/symbols/BCBA-NVS.CI/financials-statistics-and-ratios/enterprise-value-ebitda/", "source_name": "TradingView", "published_at": "2026-06-17T11:39:41", "published_display": "17 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Preferred dividends of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs \u2013 BCBA:NVS.CI", "summary": "This article briefly mentions the preferred dividends for Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs, traded on the Buenos Aires Stock Exchange under the ticker NVS.CI. The content focuses on financial data related to Novartis's preferred dividends, though specific values a", "url": "https://www.tradingview.com/symbols/BCBA-NVS.CI/financials-income-statement/preferred-dividends/", "source_name": "TradingView", "published_at": "2026-06-16T21:40:06", "published_display": "16 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study", "summary": "Novartis announced positive Phase III results for Rhapsido (remibrutinib) in treating chronic inducible urticaria (CIndU), showing statistically significant symptom control compared to placebo with a favorable safety profile. The drug met primary endpoints across three CIndU subt", "url": "https://www.tradingview.com/news/zacks:e7fe3299d094b:0-novartis-rhapsido-meets-primary-goal-in-phase-iii-skin-disorder-study/", "source_name": "TradingView", "published_at": "2026-06-15T14:40:34", "published_display": "15 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis\u2019 $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win", "summary": "Novartis is seeing positive results from its $12 billion acquisition of Avidity Biosciences, with promising biomarker findings for its RNA-based medicine delpacibart braxlosiran (del-bax) in patients with facioscapulohumeral muscular dystrophy (FSHD). The Phase 1/2 FORTITUDE stud", "url": "https://www.biospace.com/drug-development/novartis-12b-avidity-buy-pays-dividends-with-phase-1-2-muscular-dystrophy-win", "source_name": "BioSpace", "published_at": "2026-06-12T11:39:15", "published_display": "12 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis RNA Therapy Del-Brax Shows Success in Muscular Dystrophy Trial", "summary": "Novartis's RNA therapy, del-brax, has demonstrated success in a Phase 1/2 trial for facioscapulohumeral muscular dystrophy (FSHD) by reducing key biomarkers of muscle damage. The company believes del-brax could be the first disease-modifying treatment for FSHD and is currently en", "url": "https://intellectia.ai/news/stock/novartis-rna-therapy-delbrax-shows-success-in-muscular-dystrophy-trial", "source_name": "Intellectia AI", "published_at": "2026-06-12T11:39:15", "published_display": "12 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis posts trial win for muscle disease drug", "summary": "Novartis announced that its RNA therapy, braxlosiran (del-brax), acquired through its acquisition of Avidity Biosciences, succeeded in a Phase 1/2 trial for facioscapulohumeral muscular dystrophy, a rare neuromuscular disease. The drug is designed to address the abnormal expressi", "url": "https://seekingalpha.com/news/4602902-novartis-posts-trial-win-muscle-disease-drug", "source_name": "Seeking Alpha", "published_at": "2026-06-12T10:39:15", "published_display": "12 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (NOVN) Receives a Hold from Jefferies", "summary": "Jefferies analyst James Vane maintained a Hold rating on Novartis AG (NOVN) with a price target of CHF110.00. Other analysts, including James Gordon CFA from Barclays, also issued a Hold rating, while Deutsche Bank maintained a Buy rating. Novartis reported Q1 revenues of CHF12.8", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NVS/pressreleases/2436309/novartis-ag-novn-receives-a-hold-from-jefferies/", "source_name": "The Globe and Mail", "published_at": "2026-06-12T09:40:13", "published_display": "12 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis RemIND data at EAACI show Rhapsido\u00ae potential as first targeted therapy for chronic inducible urticaria (CIndU)", "summary": "Novartis presented data from the RemIND trial at the EAACI Congress, showing that Rhapsido\u00ae (remibrutinib) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes, making it the first treatment to demonstrate efficacy in a global Phase ", "url": "https://www.globenewswire.com/news-release/2026/06/12/3310932/0/en/novartis-remind-data-at-eaaci-show-rhapsido-potential-as-first-targeted-therapy-for-chronic-inducible-urticaria-cindu.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T09:39:15", "published_display": "12 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Raises Target Price to $180", "summary": "TD Cowen has reiterated its Hold rating on Novartis AG (NVS.US) and increased its price target for the company's stock to $180. This adjustment reflects the analyst firm's updated outlook on Novartis's financials and market position.", "url": "https://www.moomoo.com/news/post/71409750/td-cowen-maintains-novartis-ag-nvsus-with-hold-rating-raises", "source_name": "Moomoo", "published_at": "2026-06-12T08:10:12", "published_display": "12 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis says rare muscle disease drug shows promise in early trial", "summary": "Novartis announced that its experimental drug, del-brax, acquired through its takeover of Avidity, showed promise in an early-to-mid-stage study for facioscapulohumeral muscular dystrophy (FSHD). The drug reduced disease-linked blood markers and muscle damage signs, suggesting it", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-says-rare-muscle-disease-drug-shows-promise-early-trial-2026-06-11/", "source_name": "Reuters", "published_at": "2026-06-11T21:41:03", "published_display": "11 Jun 2026 21:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG Stock (NVS) Moved Up by 4.20% on Jun 11: What Investors Need To Know", "summary": "Novartis AG (NVS) saw its stock rise by 4.20% on June 11, driven by positive results from its FORTITUDE Phase I/II study for del-brax, an investigational drug for facioscapulohumeral muscular dystrophy (FSHD). This positive news, along with reiterated buy ratings from analysts an", "url": "https://www.tradingkey.com/news/market-movers/261961925-market-movers-nvs-20260611", "source_name": "TradingKey", "published_at": "2026-06-11T18:15:00", "published_display": "11 Jun 2026 18:15", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis Reports Positive Data for Neuromuscular Disorder Drug", "summary": "Novartis announced positive data from the biomarker cohort of its FORTITUDE phase I/II study for delpacibart braxlosiran (del-brax), an investigational therapy for facioscapulohumeral muscular dystrophy (FSHD). The study met its primary and secondary endpoints, showing reductions", "url": "https://www.tradingview.com/news/zacks:20ca63a2a094b:0-novartis-reports-positive-data-for-neuromuscular-disorder-drug/", "source_name": "TradingView", "published_at": "2026-06-11T17:11:03", "published_display": "11 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis doubles down on molecular glue strategy", "summary": "Novartis is reportedly expanding its ambitions in molecular glue strategies, a key development in the biotech sector. This news comes amidst rising Medicare drug spending, partly driven by GLP-1 medicines, and promising early data for Enliven's leukemia drug. Additionally, SonoTh", "url": "https://www.statnews.com/2026/06/11/biotech-news-novartis-doubles-down-on-molecular-glue-strategy/", "source_name": "STAT", "published_at": "2026-06-11T14:11:26", "published_display": "11 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Del-Brax Biomarker Data Offers Early Support For Novartis\u2019s Avidity Bet", "summary": "Novartis announced positive biomarker data from its FORTITUDE study for facioscapulohumeral muscular dystrophy (FSHD), which met its primary and key secondary endpoints. This development provides early validation for Novartis's investment in Avidity Biosciences, following its rec", "url": "https://insights.citeline.com/scrip/r-and-d/clinical-trials/positive-del-brax-biomarker-data-offers-early-support-for-novartiss-avidity-bet-EZGLCIXAMRDAXCK4NYYSO7AJEA/", "source_name": "Citeline News & Insights", "published_at": "2026-06-11T13:11:26", "published_display": "11 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis (NVS) reports del-brax FSHD Phase I/II biomarker success, Phase III underway", "summary": "Novartis announced that its investigational therapy delpacibart braxlosiran (del-brax) successfully met primary and key secondary biomarker endpoints in the FORTITUDE Phase I/II study for facioscapulohumeral muscular dystrophy (FSHD), showing reduced KHDC1L and creatine kinase le", "url": "https://www.stocktitan.net/sec-filings/NVS/6-k-novartis-ag-current-report-foreign-issuer-6235841d201b.html", "source_name": "Stock Titan", "published_at": "2026-06-11T12:11:26", "published_display": "11 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis and Orionis get stuck in with new \u201cmolecular glue\u201d R&D deal worth up to $1.4bn", "summary": "Novartis has expanded its agreement with Orionis in a deal potentially worth $1.4 billion to develop \"molecular glue\" drugs targeting elusive proteins. This collaboration will leverage Orionis's Allo-Glue platform and AI-driven discovery engine to identify and optimize small mole", "url": "https://european-biotechnology.com/latest-news/novartis-and-orionis-get-stuck-in-with-new-molecular-glue-rd-deal-worth-up-to-1-4bn/", "source_name": "European Biotechnology Magazine", "published_at": "2026-06-11T12:11:26", "published_display": "11 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NOVARTIS AG : Jefferies remains Neutral", "summary": "Jefferies has reiterated its \"Neutral\" rating on NOVARTIS AG, maintaining an unchanged target price of CHF 110. This analyst coverage indicates a continued stable outlook for the pharmaceutical company's stock according to Jefferies' assessment.", "url": "https://www.marketscreener.com/news/novartis-ag-jefferies-remains-neutral-ce7f5cdbd08aff24", "source_name": "www.marketscreener.com", "published_at": "2026-06-11T08:11:26", "published_display": "11 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis delpacibart braxlosiran (del-brax) Phase I/II", "summary": "Novartis announced that its delpacibart braxlosiran (del-brax) Phase I/II FORTITUDE study met its primary and key secondary endpoints, showing reductions in KHDC1L and creatine kinase levels in patients with facioscapulohumeral muscular dystrophy (FSHD). This indicates strong tar", "url": "https://www.globenewswire.com/news-release/2026/06/11/3310187/0/en/novartis-delpacibart-braxlosiran-del-brax-phase-i-ii-study-in-facioscapulohumeral-muscular-dystrophy-fshd-meets-primary-biomarker-endpoint.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T05:09:30", "published_display": "11 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis Reports Positive Biomarker Data for Del-Brax in Muscular Dystrophy Study", "summary": "Novartis has reported positive biomarker data for its drug candidate delpacibart braxlosiran (del-brax) from a Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD). The study successfully met its primary biomarker endpoint, indicating a promising step forward in the ", "url": "https://www.marketscreener.com/news/novartis-reports-positive-biomarker-data-for-del-brax-in-muscular-dystrophy-study-ce7f5cdbd188f42d", "source_name": "marketscreener.com", "published_at": "2026-06-11T05:09:30", "published_display": "11 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASCO: Novartis To Face Challenges In Growing Radiopharmaceutical Space", "summary": "Novartis is", "url": "https://insights.citeline.com/scrip/conferences/asco/asco-novartis-to-face-challenges-in-growing-radiopharmaceutical-space-ERSSTUODS5BUVBQGOKL6LNZFMU/", "source_name": "Citeline News & Insights", "published_at": "2026-06-09T21:39:53", "published_display": "09 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG stock (CH0012005267): pharma heavyweight digests Sandoz spin-off and eyes next growth wa", "summary": "Novartis AG has successfully transitioned into a focused innovative medicines company after spinning off its Sandoz generics unit. The company is now concentrating on high-value prescription drugs, supported by a strong pipeline and a strategy to enhance operational efficiency. W", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/novartis-ag-stock-ch0012005267-pharma-heavyweight-digests-sandoz/69509254", "source_name": "AD HOC NEWS", "published_at": "2026-06-09T17:10:44", "published_display": "09 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NOVARTIS AG : Deutsche Bank remains its Buy rating", "summary": "Deutsche Bank has reiterated its \"Buy\" rating for Novartis AG, maintaining a target price of CHF 135 for the stock. This recommendation was issued by Emmanuel Papadakis in a research note.", "url": "https://www.marketscreener.com/news/novartis-ag-deutsche-bank-remains-its-buy-rating-ce7f5dd3de8cf624", "source_name": "www.marketscreener.com", "published_at": "2026-06-09T04:04:00", "published_display": "09 Jun 2026 04:04", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG stock (CH0012005267): oncology focus and AI deals keep investors watching", "summary": "Novartis AG is maintaining its investor appeal through a sharpened focus on oncology, immunology, and cardiovascular diseases, coupled with strategic investments in AI and digital drug discovery. The company operates as an innovation-driven pharmaceutical group with a strong ther", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/novartis-ag-stock-ch0012005267-oncology-focus-and-ai-deals-keep/69502572", "source_name": "AD HOC NEWS", "published_at": "2026-06-08T17:09:06", "published_display": "08 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (NVS) Stock Analysis: Evaluating Growth Potential With A 3.15% Upside", "summary": "Novartis AG (NVS) is analyzed as a stable pharmaceutical giant with a market capitalization of $284.61 billion, offering a 3.18% dividend yield and a potential upside of 3.15% based on analyst consensus. Despite a slight revenue decline, the company demonstrates robust financial ", "url": "https://www.directorstalkinterviews.com/novartis-ag-nvs-stock-analysis-evaluating-growth-potential-with-a-3-15-upside/4121253112", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-08T10:17:00", "published_display": "08 Jun 2026 10:17", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis to present Rhapsido data at allergy congress", "summary": "Novartis (NYSE: NVS) is set to present data from 10 research abstracts at the 2026 European Academy of Allergy and Clinical Immunology Congress. The presentations will focus on Rhapsido (remibrutinib), its BTK inhibitor, covering its effectiveness in chronic inducible urticaria a", "url": "https://www.streetinsider.com/Corporate+News/Novartis+to+present+Rhapsido+data+at+allergy+congress/26613349.html", "source_name": "StreetInsider", "published_at": "2026-06-08T07:09:06", "published_display": "08 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis to highlight Rhapsido\u00ae data across multiple immune-mediated diseases at EAACI Congress 2026", "summary": "Novartis will present data from its Rhapsido (remibrutinib) clinical trials at the EAACI Congress 2026, focusing on its efficacy and safety in various immune-mediated diseases. Key highlights include pivotal Phase III RemIND trial results for chronic inducible urticaria and Phase", "url": "https://www.globenewswire.com/news-release/2026/06/08/3307813/0/en/novartis-to-highlight-rhapsido-data-across-multiple-immune-mediated-diseases-at-eaaci-congress-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T07:09:06", "published_display": "08 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG Falls Monday", "summary": "The article reports that Novartis AG (NYSE:NVS) experienced a decline in stock value on Monday, falling towards its 52-week low.", "url": "https://www.moomoo.com/news/post/71211900/novartis-ag-falls-monday", "source_name": "Moomoo", "published_at": "2026-06-07T23:10:49", "published_display": "07 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argus Research Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $160", "summary": "Argus Research has initiated coverage on Novartis AG (NVS.US) with a \"Buy\" rating. The firm has set a target price of $160 for the pharmaceutical company's stock. This indicates Argus Research's positive outlook on Novartis's future performance.", "url": "https://www.moomoo.com/news/post/71139978/argus-research-initiates-novartis-ag-nvsus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-06T18:09:06", "published_display": "06 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EULAR: Novartis Closes In On Final Approval For Cosentyx", "summary": "Novartis is nearing final approval for its drug Cosentyx for polymyalgia rheumatica (PMR). This approval is expected to further boost Cosentyx's already strong sales figures. The article was published on June 5, 2026, according to its internal timestamp.", "url": "https://insights.citeline.com/scrip/r-and-d/eular-novartis-closes-in-on-final-approval-for-cosentyx-FLZQNDM3P5C35KRO3CDAMQXWYE/", "source_name": "Citeline News & Insights", "published_at": "2026-06-06T05:10:04", "published_display": "06 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG Stock (NVS) Closed Up by 3.12% on Jun 4: A Full Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOdXA4dHhHak9mc29GY1RScXF1S2RVSlB4RTJoWWpWUXpmZUhiS2w5ZWN3aFRPTVRmZ1U2UEMycTl5OUtpLWhTX1ZsYmppa3JqclVZOUhsYk50N3hYa2dnOGV2RFhXbnoyWE0xdXNsMEZlQmhCOHFwamt4NGtBRmJPalNhMFlJRWVNX0E?oc=5", "source_name": "TradingKey", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG Stock (NVS) Moved Down by 3.14% on Jun 1: Key Drivers Unveiled", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNSWMxOXhqY0Y5MHFWdE5RYlZIeG8zdEQtSDdMSmxqcllNU1VBTEl5OFA1VlY5eHJiRC1scFBrdVdwTUM4UHNWU1NvckZMbGVITFVtSmgtMG8tRkxzaWZkU3FJWTFnLTMtbTBHSEJHVnBXN0dwREczU0c2eDJIQmxRX1NzUXBvNkZpUnc?oc=5", "source_name": "TradingKey", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (ADR) stock (CH0012005267): steady trading ahead of next catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOMi1zQmlDOHIxdzI5YTNiWUtGeEl4WV95eDFMQjBBXzZZOUI1MkdaRVZ4b0xPZHZYenVJNzdadjVseDBnQVZZeU96TE5hWEVIVnZxXzEzVW14M1RaUjhfOW81bWN3YmR5dlBNcW1oaUx2VWdIVkJ4UF9OZmtSekVYRW1Gb2o1OHRTRnRtNkh5ZjNFcWdibUxmejNqbkFiYU5waTh3MzZxTDFoYzNhMkxfcG52YkdKTkRBV2Q1Q2dpYw?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (NVS) Stock Analysis: Strong ROE And Strategic Focus Positioning For Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOcUlLNFl3TllTUkxLSWxIa1pEbng0MjNCMXlhOTNULU04RFpiOHViY0dmOXhFZzdhYTJsYk1IYkIwRHo2UWlyanJ3VXpuVXcyal9yQ05LakgtLVlRc2VudzZvZEZlZ0MyMXNCV1JEdXBKOHRKQ2FPeWJuVDJpbHRjR3pmVnFiVGxPX21FZ1AzR3MzUFJqZTI4TXROWWNOT0xtLWx6cFhXWU1LTTBIaGpYek5aTzV0aEpWbFlOMEFEaHlya3BuOGNQNUc0MEc3bDBk?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis (NVS) Positioned for Growth Through Transformative Innovations", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxONHZMV3plbW13dmtjMWs3RG1VMVNfelFTa0ZqeUZNaEptS1IteTdwbVNVcnotNWFSdHBudXRRbjlxektpaXB3XzhCSk1fVXZyNm9tS0dqdk1ORHR2WDk3Yjk1M0dEa0RjLXRMLXRzRGZ2bHFrNUpFZE1QOWdwa0tid3hPYjlGZTF3QUFENVdpcnBhM2Y2SmMyQUVPcWhYT1VMOFRpdVI1MWFDMDBTTHdTX0FtdWk?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Implied Volatility Surging for Novartis Stock Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPTUxORWp4ZUdKRE1UYU1DVjRBY2pXbmdkMDQwMVk0VVVHdTU0SUNUVlZGRXpELWZ6WDFTNms2a0hCam1PUGpwVnRSdzZrRmF0U3YzTm1TX19LZG9pdDN1aXVsNUZ6ejBRTTR5WUZlT3dEd0xiNHNzUmtqLTZsNldodTlJbklobjNoY1Zxc3JhTW4?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis (NVS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPcXM1dEZIVDJiMjVzNHp3VFZKNWRIY2JpTkdsSmVEYnh2di03bWt2UDZQVDIwTlFTZnNNUXFpWWNSSkItM01JT205S0tsN3E1VFBSR2VreVQ2cW8tX0p5REVBR2FHT2ZBOUl5QXlWdTFNZjRUVTVTR3JCdWdIMExsZjU0MHd6Wnp1dS1zX1NBYmVIZE5EQ2xNVA?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (NVS): One of the Best Low Risk High Growth Plays on the Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQTllaVHN2Q3BvQktQMjRXclVHY0xRcVR0ZUxVM25uQnJCNklMTVcyS19wcXQxQVBOLUx1SG81eVFoZFQwUzJHVGRGQ1NyMnNvc1VLX1VtX25GWS1tZkNMd0JmSUtWTkk4Z0QtQkhZdXRGeF95SkhqaXlINEEtVUlZSE1wMWhNQ0lxSDYycW1rbnZRck5sWlFjeQ?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis stock hits all-time high at 153.83 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQSkNJRVRJaGpxeEU3bEtwTF8xbmVpNjh1d05qS2RiSXFzOUYtQUgwVEhob2hkZXg3STAwQWV4RzVfMWtiMW5vTXl1ZFJtSWZYQ29VQm9KVkJLU3hlTHUyWkdxZnZlbGhTV183X2tnZHZtLWVGQk1PZUpLY0RmMEhjSnVwQWxfOW5iSzNMZElYU0FZTXIzalBJeTIwNEE4dllKVDZUTw?oc=5", "source_name": "Investing.com", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exploring Analyst Estimates for Novartis (NVS) Q4 Earnings, Beyond Revenue and EPS", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQNENVZ1dKaENzZXRDNlBpbHhlNWVqRm1FVnkzbV90bHJKNFFmRXhFd1kxZ2h4c3Mzdkdjbm5sYS1oZ1V4RTJyMTQ4WFZPQjZyamJqRFFZV0JmODVpbXJLZk1oak5Fd0I4b1g4bGsxam5Mdm1hWllhbDgtbGRYWDJ2cGQ3OU9WVkhaRmZIZm9DQQ?oc=5", "source_name": "Market source", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock Backed by Strong Fundamentals", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQWkhZam9NYXhERkpjUW1TU0JTNDktN1hRcU5Xb0d3VTRUZld0cEtyT2NNcGhYZk1PSE1LcEhzbUVGU2hPRHZ1NDFZcjFMNTY5Zl9RdE81UzZ3Yl80bmFnNUtTY0U0STBWVGpkNWtiSDZMNG9FR3FMU29BUGlrSVBkd05Ya3pVeTBQZGhEUjhiNW1tUzFrQkFjQ0Q4WWo0MVNPM2FZX3RzZmx0cFA5d1o2NG9ld0xwNkw0MXIxUTF3X1l2Z0FBRDcwdnlIcmhtYkhXa1RENXl3?oc=5", "source_name": "ChartMill", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis stock hits all-time high at $146.4", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQU3JLSDM5VG82SFRYMEo2RDVESk1xY0R4MUdNTnp2OHVPU3lxcS1sVjRBQUFURV9NemNMZEVpN3B3OUp5WVdodGFDYkRUUGpnMkNPVXVlWnVqYjhvUldRVnlWQWNQNzh4cHVTTnNQcEJITmszdkRzc19Eb3l6a0ZSeXVTNTFMNlhEbE1qWGlJU25Eb0ktRFd2cjY0X1lVUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPOFRpYkxSMWd6azVZZ2YtT0dJRTVDRlEySmltRXA3QlUtY05DOGFRM2RMd2pHUUlidldSZHBhRTdZT1hkMG9qODMtQ1AyMjBxOVZjT1R4TWw4QTB4bFB3X0VsU3puYnNOM2M0MHpIQmFxVGdUbWgwOEp4M2U4Q2dwMU9zaW43dWlkNXc?oc=5", "source_name": "Market source", "published_at": "2025-10-22T07:00:00+00:00", "published_display": "22 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Novartis (NVS) is a Top Momentum Stock for the Long-Term", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNb3N2Rnp2M19RR2RMMmVta0dEdVMyeWNNbmY0dERfLUN5VlY2M0lpRFM3ZXctaDl3X1hNYjV3OEVDWFByV1dOV3dKZjViSENSTGZZNEg4WGtKdFNfRUlHa29rdFJzdjRoYkxpVWFtX2NTdXNXQWdtQzdVTFc1ODZyaA?oc=5", "source_name": "Market source", "published_at": "2025-10-06T07:00:00+00:00", "published_display": "06 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (NVS) Stock Price, Trades & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE16cGZ0Zzd5X0U1eFp4U1NYRUZMQUhwSTdWN1hJc0tTc29XZWFwZ1JIZlR2MnR4NU43dkN3UUMtMnZ1V3Y0TDY4M081aWF5UDRpWmdYX1d3?oc=5", "source_name": "GuruFocus", "published_at": "2019-04-15T21:08:05+00:00", "published_display": "15 Apr 2019 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Novartis AG (NVS): 7 Best Longevity and Anti-Aging Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPckZUd2pEUzRHRV9vSDhhWWxEUDNHM3VMOUw5aHhoN0Z0S1FsY2t6ZjhQMEpNVlF3RVdIWjU2Rlh6X2JUd0t3U0tuV2xmUHhXUG9SZTlzTV9KcmJDaXMyODA4Skk4Z254QkhHdE5mNGl5MWczWlV0V3F3R0ZjZnZuS1NYb0JiTHRxdWcw?oc=5", "source_name": "Market source", "published_at": "2026-06-22T13:10:10+00:00", "published_display": "22 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NOVARTIS AG-SPONSORED ADR (NVS) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE9OTk9GT29Lc2lhZy1mYk9fclh0VDlfbmp1SWJOT0tjaV9Ld3VSMWQyT1Byek9sM2NYMUZTRk9yeUdiVk9raXE0czZTUXRiY256RjVWdWZTQ2dXdXMyMU83Sll6SQ?oc=5", "source_name": "ChartMill", "published_at": "2026-06-19T00:19:39+00:00", "published_display": "19 Jun 2026 00:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5oRllyQi14b3ZkUWN4TVRPSUNpUXZxbkFaSE1PTDZGWldOMDJpTlZMaUM4V3dTQ2FtaGZ1cmk5dnNOdWJ4Q2JYUGkxVm1VVFR0M2FBcDFXSDExQQ?oc=5", "source_name": "ChartMill", "published_at": "2026-06-19T00:19:39+00:00", "published_display": "19 Jun 2026 00:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA ratio of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs \u2013 BCBA:NVS.CI", "summary": "This article provides access to the enterprise value to EBITDA ratio for Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs, traded on the Buenos Aires Stock Exchange under the ticker NVS.CI. It appears to be a financial data page from TradingView, offering financial metrics for th", "url": "https://www.tradingview.com/symbols/BCBA-NVS.CI/financials-statistics-and-ratios/enterprise-value-ebitda/", "source_name": "TradingView", "published_at": "2026-06-17T11:39:41", "published_display": "17 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Preferred dividends of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs \u2013 BCBA:NVS.CI", "summary": "This article briefly mentions the preferred dividends for Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs, traded on the Buenos Aires Stock Exchange under the ticker NVS.CI. The content focuses on financial data related to Novartis's preferred dividends, though specific values a", "url": "https://www.tradingview.com/symbols/BCBA-NVS.CI/financials-income-statement/preferred-dividends/", "source_name": "TradingView", "published_at": "2026-06-16T21:40:06", "published_display": "16 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study", "summary": "Novartis announced positive Phase III results for Rhapsido (remibrutinib) in treating chronic inducible urticaria (CIndU), showing statistically significant symptom control compared to placebo with a favorable safety profile. The drug met primary endpoints across three CIndU subt", "url": "https://www.tradingview.com/news/zacks:e7fe3299d094b:0-novartis-rhapsido-meets-primary-goal-in-phase-iii-skin-disorder-study/", "source_name": "TradingView", "published_at": "2026-06-15T14:40:34", "published_display": "15 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis\u2019 $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win", "summary": "Novartis is seeing positive results from its $12 billion acquisition of Avidity Biosciences, with promising biomarker findings for its RNA-based medicine delpacibart braxlosiran (del-bax) in patients with facioscapulohumeral muscular dystrophy (FSHD). The Phase 1/2 FORTITUDE stud", "url": "https://www.biospace.com/drug-development/novartis-12b-avidity-buy-pays-dividends-with-phase-1-2-muscular-dystrophy-win", "source_name": "BioSpace", "published_at": "2026-06-12T11:39:15", "published_display": "12 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis RNA Therapy Del-Brax Shows Success in Muscular Dystrophy Trial", "summary": "Novartis's RNA therapy, del-brax, has demonstrated success in a Phase 1/2 trial for facioscapulohumeral muscular dystrophy (FSHD) by reducing key biomarkers of muscle damage. The company believes del-brax could be the first disease-modifying treatment for FSHD and is currently en", "url": "https://intellectia.ai/news/stock/novartis-rna-therapy-delbrax-shows-success-in-muscular-dystrophy-trial", "source_name": "Intellectia AI", "published_at": "2026-06-12T11:39:15", "published_display": "12 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis posts trial win for muscle disease drug", "summary": "Novartis announced that its RNA therapy, braxlosiran (del-brax), acquired through its acquisition of Avidity Biosciences, succeeded in a Phase 1/2 trial for facioscapulohumeral muscular dystrophy, a rare neuromuscular disease. The drug is designed to address the abnormal expressi", "url": "https://seekingalpha.com/news/4602902-novartis-posts-trial-win-muscle-disease-drug", "source_name": "Seeking Alpha", "published_at": "2026-06-12T10:39:15", "published_display": "12 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (NOVN) Receives a Hold from Jefferies", "summary": "Jefferies analyst James Vane maintained a Hold rating on Novartis AG (NOVN) with a price target of CHF110.00. Other analysts, including James Gordon CFA from Barclays, also issued a Hold rating, while Deutsche Bank maintained a Buy rating. Novartis reported Q1 revenues of CHF12.8", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NVS/pressreleases/2436309/novartis-ag-novn-receives-a-hold-from-jefferies/", "source_name": "The Globe and Mail", "published_at": "2026-06-12T09:40:13", "published_display": "12 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis RemIND data at EAACI show Rhapsido\u00ae potential as first targeted therapy for chronic inducible urticaria (CIndU)", "summary": "Novartis presented data from the RemIND trial at the EAACI Congress, showing that Rhapsido\u00ae (remibrutinib) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes, making it the first treatment to demonstrate efficacy in a global Phase ", "url": "https://www.globenewswire.com/news-release/2026/06/12/3310932/0/en/novartis-remind-data-at-eaaci-show-rhapsido-potential-as-first-targeted-therapy-for-chronic-inducible-urticaria-cindu.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T09:39:15", "published_display": "12 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Raises Target Price to $180", "summary": "TD Cowen has reiterated its Hold rating on Novartis AG (NVS.US) and increased its price target for the company's stock to $180. This adjustment reflects the analyst firm's updated outlook on Novartis's financials and market position.", "url": "https://www.moomoo.com/news/post/71409750/td-cowen-maintains-novartis-ag-nvsus-with-hold-rating-raises", "source_name": "Moomoo", "published_at": "2026-06-12T08:10:12", "published_display": "12 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis says rare muscle disease drug shows promise in early trial", "summary": "Novartis announced that its experimental drug, del-brax, acquired through its takeover of Avidity, showed promise in an early-to-mid-stage study for facioscapulohumeral muscular dystrophy (FSHD). The drug reduced disease-linked blood markers and muscle damage signs, suggesting it", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-says-rare-muscle-disease-drug-shows-promise-early-trial-2026-06-11/", "source_name": "Reuters", "published_at": "2026-06-11T21:41:03", "published_display": "11 Jun 2026 21:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG Stock (NVS) Moved Up by 4.20% on Jun 11: What Investors Need To Know", "summary": "Novartis AG (NVS) saw its stock rise by 4.20% on June 11, driven by positive results from its FORTITUDE Phase I/II study for del-brax, an investigational drug for facioscapulohumeral muscular dystrophy (FSHD). This positive news, along with reiterated buy ratings from analysts an", "url": "https://www.tradingkey.com/news/market-movers/261961925-market-movers-nvs-20260611", "source_name": "TradingKey", "published_at": "2026-06-11T18:15:00", "published_display": "11 Jun 2026 18:15", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis Reports Positive Data for Neuromuscular Disorder Drug", "summary": "Novartis announced positive data from the biomarker cohort of its FORTITUDE phase I/II study for delpacibart braxlosiran (del-brax), an investigational therapy for facioscapulohumeral muscular dystrophy (FSHD). The study met its primary and secondary endpoints, showing reductions", "url": "https://www.tradingview.com/news/zacks:20ca63a2a094b:0-novartis-reports-positive-data-for-neuromuscular-disorder-drug/", "source_name": "TradingView", "published_at": "2026-06-11T17:11:03", "published_display": "11 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis doubles down on molecular glue strategy", "summary": "Novartis is reportedly expanding its ambitions in molecular glue strategies, a key development in the biotech sector. This news comes amidst rising Medicare drug spending, partly driven by GLP-1 medicines, and promising early data for Enliven's leukemia drug. Additionally, SonoTh", "url": "https://www.statnews.com/2026/06/11/biotech-news-novartis-doubles-down-on-molecular-glue-strategy/", "source_name": "STAT", "published_at": "2026-06-11T14:11:26", "published_display": "11 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Del-Brax Biomarker Data Offers Early Support For Novartis\u2019s Avidity Bet", "summary": "Novartis announced positive biomarker data from its FORTITUDE study for facioscapulohumeral muscular dystrophy (FSHD), which met its primary and key secondary endpoints. This development provides early validation for Novartis's investment in Avidity Biosciences, following its rec", "url": "https://insights.citeline.com/scrip/r-and-d/clinical-trials/positive-del-brax-biomarker-data-offers-early-support-for-novartiss-avidity-bet-EZGLCIXAMRDAXCK4NYYSO7AJEA/", "source_name": "Citeline News & Insights", "published_at": "2026-06-11T13:11:26", "published_display": "11 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis (NVS) reports del-brax FSHD Phase I/II biomarker success, Phase III underway", "summary": "Novartis announced that its investigational therapy delpacibart braxlosiran (del-brax) successfully met primary and key secondary biomarker endpoints in the FORTITUDE Phase I/II study for facioscapulohumeral muscular dystrophy (FSHD), showing reduced KHDC1L and creatine kinase le", "url": "https://www.stocktitan.net/sec-filings/NVS/6-k-novartis-ag-current-report-foreign-issuer-6235841d201b.html", "source_name": "Stock Titan", "published_at": "2026-06-11T12:11:26", "published_display": "11 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis and Orionis get stuck in with new \u201cmolecular glue\u201d R&D deal worth up to $1.4bn", "summary": "Novartis has expanded its agreement with Orionis in a deal potentially worth $1.4 billion to develop \"molecular glue\" drugs targeting elusive proteins. This collaboration will leverage Orionis's Allo-Glue platform and AI-driven discovery engine to identify and optimize small mole", "url": "https://european-biotechnology.com/latest-news/novartis-and-orionis-get-stuck-in-with-new-molecular-glue-rd-deal-worth-up-to-1-4bn/", "source_name": "European Biotechnology Magazine", "published_at": "2026-06-11T12:11:26", "published_display": "11 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NOVARTIS AG : Jefferies remains Neutral", "summary": "Jefferies has reiterated its \"Neutral\" rating on NOVARTIS AG, maintaining an unchanged target price of CHF 110. This analyst coverage indicates a continued stable outlook for the pharmaceutical company's stock according to Jefferies' assessment.", "url": "https://www.marketscreener.com/news/novartis-ag-jefferies-remains-neutral-ce7f5cdbd08aff24", "source_name": "www.marketscreener.com", "published_at": "2026-06-11T08:11:26", "published_display": "11 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis delpacibart braxlosiran (del-brax) Phase I/II", "summary": "Novartis announced that its delpacibart braxlosiran (del-brax) Phase I/II FORTITUDE study met its primary and key secondary endpoints, showing reductions in KHDC1L and creatine kinase levels in patients with facioscapulohumeral muscular dystrophy (FSHD). This indicates strong tar", "url": "https://www.globenewswire.com/news-release/2026/06/11/3310187/0/en/novartis-delpacibart-braxlosiran-del-brax-phase-i-ii-study-in-facioscapulohumeral-muscular-dystrophy-fshd-meets-primary-biomarker-endpoint.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T05:09:30", "published_display": "11 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis Reports Positive Biomarker Data for Del-Brax in Muscular Dystrophy Study", "summary": "Novartis has reported positive biomarker data for its drug candidate delpacibart braxlosiran (del-brax) from a Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD). The study successfully met its primary biomarker endpoint, indicating a promising step forward in the ", "url": "https://www.marketscreener.com/news/novartis-reports-positive-biomarker-data-for-del-brax-in-muscular-dystrophy-study-ce7f5cdbd188f42d", "source_name": "marketscreener.com", "published_at": "2026-06-11T05:09:30", "published_display": "11 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASCO: Novartis To Face Challenges In Growing Radiopharmaceutical Space", "summary": "Novartis is", "url": "https://insights.citeline.com/scrip/conferences/asco/asco-novartis-to-face-challenges-in-growing-radiopharmaceutical-space-ERSSTUODS5BUVBQGOKL6LNZFMU/", "source_name": "Citeline News & Insights", "published_at": "2026-06-09T21:39:53", "published_display": "09 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG stock (CH0012005267): pharma heavyweight digests Sandoz spin-off and eyes next growth wa", "summary": "Novartis AG has successfully transitioned into a focused innovative medicines company after spinning off its Sandoz generics unit. The company is now concentrating on high-value prescription drugs, supported by a strong pipeline and a strategy to enhance operational efficiency. W", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/novartis-ag-stock-ch0012005267-pharma-heavyweight-digests-sandoz/69509254", "source_name": "AD HOC NEWS", "published_at": "2026-06-09T17:10:44", "published_display": "09 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NOVARTIS AG : Deutsche Bank remains its Buy rating", "summary": "Deutsche Bank has reiterated its \"Buy\" rating for Novartis AG, maintaining a target price of CHF 135 for the stock. This recommendation was issued by Emmanuel Papadakis in a research note.", "url": "https://www.marketscreener.com/news/novartis-ag-deutsche-bank-remains-its-buy-rating-ce7f5dd3de8cf624", "source_name": "www.marketscreener.com", "published_at": "2026-06-09T04:04:00", "published_display": "09 Jun 2026 04:04", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG stock (CH0012005267): oncology focus and AI deals keep investors watching", "summary": "Novartis AG is maintaining its investor appeal through a sharpened focus on oncology, immunology, and cardiovascular diseases, coupled with strategic investments in AI and digital drug discovery. The company operates as an innovation-driven pharmaceutical group with a strong ther", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/novartis-ag-stock-ch0012005267-oncology-focus-and-ai-deals-keep/69502572", "source_name": "AD HOC NEWS", "published_at": "2026-06-08T17:09:06", "published_display": "08 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (NVS) Stock Analysis: Evaluating Growth Potential With A 3.15% Upside", "summary": "Novartis AG (NVS) is analyzed as a stable pharmaceutical giant with a market capitalization of $284.61 billion, offering a 3.18% dividend yield and a potential upside of 3.15% based on analyst consensus. Despite a slight revenue decline, the company demonstrates robust financial ", "url": "https://www.directorstalkinterviews.com/novartis-ag-nvs-stock-analysis-evaluating-growth-potential-with-a-3-15-upside/4121253112", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-08T10:17:00", "published_display": "08 Jun 2026 10:17", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis to present Rhapsido data at allergy congress", "summary": "Novartis (NYSE: NVS) is set to present data from 10 research abstracts at the 2026 European Academy of Allergy and Clinical Immunology Congress. The presentations will focus on Rhapsido (remibrutinib), its BTK inhibitor, covering its effectiveness in chronic inducible urticaria a", "url": "https://www.streetinsider.com/Corporate+News/Novartis+to+present+Rhapsido+data+at+allergy+congress/26613349.html", "source_name": "StreetInsider", "published_at": "2026-06-08T07:09:06", "published_display": "08 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis to highlight Rhapsido\u00ae data across multiple immune-mediated diseases at EAACI Congress 2026", "summary": "Novartis will present data from its Rhapsido (remibrutinib) clinical trials at the EAACI Congress 2026, focusing on its efficacy and safety in various immune-mediated diseases. Key highlights include pivotal Phase III RemIND trial results for chronic inducible urticaria and Phase", "url": "https://www.globenewswire.com/news-release/2026/06/08/3307813/0/en/novartis-to-highlight-rhapsido-data-across-multiple-immune-mediated-diseases-at-eaaci-congress-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T07:09:06", "published_display": "08 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG Falls Monday", "summary": "The article reports that Novartis AG (NYSE:NVS) experienced a decline in stock value on Monday, falling towards its 52-week low.", "url": "https://www.moomoo.com/news/post/71211900/novartis-ag-falls-monday", "source_name": "Moomoo", "published_at": "2026-06-07T23:10:49", "published_display": "07 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Argus Research Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $160", "summary": "Argus Research has initiated coverage on Novartis AG (NVS.US) with a \"Buy\" rating. The firm has set a target price of $160 for the pharmaceutical company's stock. This indicates Argus Research's positive outlook on Novartis's future performance.", "url": "https://www.moomoo.com/news/post/71139978/argus-research-initiates-novartis-ag-nvsus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-06T18:09:06", "published_display": "06 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EULAR: Novartis Closes In On Final Approval For Cosentyx", "summary": "Novartis is nearing final approval for its drug Cosentyx for polymyalgia rheumatica (PMR). This approval is expected to further boost Cosentyx's already strong sales figures. The article was published on June 5, 2026, according to its internal timestamp.", "url": "https://insights.citeline.com/scrip/r-and-d/eular-novartis-closes-in-on-final-approval-for-cosentyx-FLZQNDM3P5C35KRO3CDAMQXWYE/", "source_name": "Citeline News & Insights", "published_at": "2026-06-06T05:10:04", "published_display": "06 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG Stock (NVS) Closed Up by 3.12% on Jun 4: A Full Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOdXA4dHhHak9mc29GY1RScXF1S2RVSlB4RTJoWWpWUXpmZUhiS2w5ZWN3aFRPTVRmZ1U2UEMycTl5OUtpLWhTX1ZsYmppa3JqclVZOUhsYk50N3hYa2dnOGV2RFhXbnoyWE0xdXNsMEZlQmhCOHFwamt4NGtBRmJPalNhMFlJRWVNX0E?oc=5", "source_name": "TradingKey", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG Stock (NVS) Moved Down by 3.14% on Jun 1: Key Drivers Unveiled", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNSWMxOXhqY0Y5MHFWdE5RYlZIeG8zdEQtSDdMSmxqcllNU1VBTEl5OFA1VlY5eHJiRC1scFBrdVdwTUM4UHNWU1NvckZMbGVITFVtSmgtMG8tRkxzaWZkU3FJWTFnLTMtbTBHSEJHVnBXN0dwREczU0c2eDJIQmxRX1NzUXBvNkZpUnc?oc=5", "source_name": "TradingKey", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (ADR) stock (CH0012005267): steady trading ahead of next catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOMi1zQmlDOHIxdzI5YTNiWUtGeEl4WV95eDFMQjBBXzZZOUI1MkdaRVZ4b0xPZHZYenVJNzdadjVseDBnQVZZeU96TE5hWEVIVnZxXzEzVW14M1RaUjhfOW81bWN3YmR5dlBNcW1oaUx2VWdIVkJ4UF9OZmtSekVYRW1Gb2o1OHRTRnRtNkh5ZjNFcWdibUxmejNqbkFiYU5waTh3MzZxTDFoYzNhMkxfcG52YkdKTkRBV2Q1Q2dpYw?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (NVS) Stock Analysis: Strong ROE And Strategic Focus Positioning For Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOcUlLNFl3TllTUkxLSWxIa1pEbng0MjNCMXlhOTNULU04RFpiOHViY0dmOXhFZzdhYTJsYk1IYkIwRHo2UWlyanJ3VXpuVXcyal9yQ05LakgtLVlRc2VudzZvZEZlZ0MyMXNCV1JEdXBKOHRKQ2FPeWJuVDJpbHRjR3pmVnFiVGxPX21FZ1AzR3MzUFJqZTI4TXROWWNOT0xtLWx6cFhXWU1LTTBIaGpYek5aTzV0aEpWbFlOMEFEaHlya3BuOGNQNUc0MEc3bDBk?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis (NVS) Positioned for Growth Through Transformative Innovations", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxONHZMV3plbW13dmtjMWs3RG1VMVNfelFTa0ZqeUZNaEptS1IteTdwbVNVcnotNWFSdHBudXRRbjlxektpaXB3XzhCSk1fVXZyNm9tS0dqdk1ORHR2WDk3Yjk1M0dEa0RjLXRMLXRzRGZ2bHFrNUpFZE1QOWdwa0tid3hPYjlGZTF3QUFENVdpcnBhM2Y2SmMyQUVPcWhYT1VMOFRpdVI1MWFDMDBTTHdTX0FtdWk?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Implied Volatility Surging for Novartis Stock Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPTUxORWp4ZUdKRE1UYU1DVjRBY2pXbmdkMDQwMVk0VVVHdTU0SUNUVlZGRXpELWZ6WDFTNms2a0hCam1PUGpwVnRSdzZrRmF0U3YzTm1TX19LZG9pdDN1aXVsNUZ6ejBRTTR5WUZlT3dEd0xiNHNzUmtqLTZsNldodTlJbklobjNoY1Zxc3JhTW4?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis (NVS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPcXM1dEZIVDJiMjVzNHp3VFZKNWRIY2JpTkdsSmVEYnh2di03bWt2UDZQVDIwTlFTZnNNUXFpWWNSSkItM01JT205S0tsN3E1VFBSR2VreVQ2cW8tX0p5REVBR2FHT2ZBOUl5QXlWdTFNZjRUVTVTR3JCdWdIMExsZjU0MHd6Wnp1dS1zX1NBYmVIZE5EQ2xNVA?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (NVS): One of the Best Low Risk High Growth Plays on the Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQTllaVHN2Q3BvQktQMjRXclVHY0xRcVR0ZUxVM25uQnJCNklMTVcyS19wcXQxQVBOLUx1SG81eVFoZFQwUzJHVGRGQ1NyMnNvc1VLX1VtX25GWS1tZkNMd0JmSUtWTkk4Z0QtQkhZdXRGeF95SkhqaXlINEEtVUlZSE1wMWhNQ0lxSDYycW1rbnZRck5sWlFjeQ?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis stock hits all-time high at 153.83 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQSkNJRVRJaGpxeEU3bEtwTF8xbmVpNjh1d05qS2RiSXFzOUYtQUgwVEhob2hkZXg3STAwQWV4RzVfMWtiMW5vTXl1ZFJtSWZYQ29VQm9KVkJLU3hlTHUyWkdxZnZlbGhTV183X2tnZHZtLWVGQk1PZUpLY0RmMEhjSnVwQWxfOW5iSzNMZElYU0FZTXIzalBJeTIwNEE4dllKVDZUTw?oc=5", "source_name": "Investing.com", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exploring Analyst Estimates for Novartis (NVS) Q4 Earnings, Beyond Revenue and EPS", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQNENVZ1dKaENzZXRDNlBpbHhlNWVqRm1FVnkzbV90bHJKNFFmRXhFd1kxZ2h4c3Mzdkdjbm5sYS1oZ1V4RTJyMTQ4WFZPQjZyamJqRFFZV0JmODVpbXJLZk1oak5Fd0I4b1g4bGsxam5Mdm1hWllhbDgtbGRYWDJ2cGQ3OU9WVkhaRmZIZm9DQQ?oc=5", "source_name": "Market source", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock Backed by Strong Fundamentals", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQWkhZam9NYXhERkpjUW1TU0JTNDktN1hRcU5Xb0d3VTRUZld0cEtyT2NNcGhYZk1PSE1LcEhzbUVGU2hPRHZ1NDFZcjFMNTY5Zl9RdE81UzZ3Yl80bmFnNUtTY0U0STBWVGpkNWtiSDZMNG9FR3FMU29BUGlrSVBkd05Ya3pVeTBQZGhEUjhiNW1tUzFrQkFjQ0Q4WWo0MVNPM2FZX3RzZmx0cFA5d1o2NG9ld0xwNkw0MXIxUTF3X1l2Z0FBRDcwdnlIcmhtYkhXa1RENXl3?oc=5", "source_name": "ChartMill", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis stock hits all-time high at $146.4", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQU3JLSDM5VG82SFRYMEo2RDVESk1xY0R4MUdNTnp2OHVPU3lxcS1sVjRBQUFURV9NemNMZEVpN3B3OUp5WVdodGFDYkRUUGpnMkNPVXVlWnVqYjhvUldRVnlWQWNQNzh4cHVTTnNQcEJITmszdkRzc19Eb3l6a0ZSeXVTNTFMNlhEbE1qWGlJU25Eb0ktRFd2cjY0X1lVUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPOFRpYkxSMWd6azVZZ2YtT0dJRTVDRlEySmltRXA3QlUtY05DOGFRM2RMd2pHUUlidldSZHBhRTdZT1hkMG9qODMtQ1AyMjBxOVZjT1R4TWw4QTB4bFB3X0VsU3puYnNOM2M0MHpIQmFxVGdUbWgwOEp4M2U4Q2dwMU9zaW43dWlkNXc?oc=5", "source_name": "Market source", "published_at": "2025-10-22T07:00:00+00:00", "published_display": "22 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Novartis (NVS) is a Top Momentum Stock for the Long-Term", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNb3N2Rnp2M19RR2RMMmVta0dEdVMyeWNNbmY0dERfLUN5VlY2M0lpRFM3ZXctaDl3X1hNYjV3OEVDWFByV1dOV3dKZjViSENSTGZZNEg4WGtKdFNfRUlHa29rdFJzdjRoYkxpVWFtX2NTdXNXQWdtQzdVTFc1ODZyaA?oc=5", "source_name": "Market source", "published_at": "2025-10-06T07:00:00+00:00", "published_display": "06 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (NVS) Stock Price, Trades & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE16cGZ0Zzd5X0U1eFp4U1NYRUZMQUhwSTdWN1hJc0tTc29XZWFwZ1JIZlR2MnR4NU43dkN3UUMtMnZ1V3Y0TDY4M081aWF5UDRpWmdYX1d3?oc=5", "source_name": "GuruFocus", "published_at": "2019-04-15T21:08:05+00:00", "published_display": "15 Apr 2019 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 109, "total_relevant": 47, "sentiment_summary": {"positive": 24, "negative": 2, "neutral": 21, "score": 62, "total": 47, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 2.0, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 24, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 147.08, "latest_week": "2026-06-19", "one_week_move": -3.9, "four_week_move": -3.2, "twelve_week_move": -0.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.693906, "market_dynamics_buy_signal": false, "relative_strength": -1.961244, "fair_value_gap": 33.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 57.9228, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.9% over one week, -3.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 73, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Market update", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "TradingView", "count": 4}, {"label": "ChartMill", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "Citeline News & Insights", "count": 3}, {"label": "AD HOC NEWS", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 5}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 4}, {"label": "Deals and strategy", "count": 3}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "62/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Market update", "tone": "positive", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.9% over one week, -3.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Novartis AG (NVS): 7 Best Longevity and Anti-Aging Stocks to Buy"}], "updated_at": "2026-06-22T22:50:28.366337+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}